India · Delayed Price · Currency is INR Concord Biotech Statistics
Total Valuation
Concord Biotech has a market cap or net worth of INR 123.91 billion. The enterprise value is 120.60 billion.
| Market Cap | 123.91B |
| Enterprise Value | 120.60B |
Important Dates
The last earnings date was Wednesday, February 11, 2026.
| Earnings Date | Feb 11, 2026 |
| Ex-Dividend Date | Sep 3, 2025 |
Share Statistics
| Current Share Class | 104.62M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.63% |
| Shares Change (QoQ) | +0.57% |
| Owned by Insiders (%) | 60.90% |
| Owned by Institutions (%) | 15.10% |
| Float | 26.59M |
Valuation Ratios
The trailing PE ratio is 39.65 and the forward PE ratio is 30.94.
| PE Ratio | 39.65 |
| Forward PE | 30.94 |
| PS Ratio | 10.69 |
| PB Ratio | 6.78 |
| P/TBV Ratio | 6.79 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 38.59 |
| EV / Sales | 10.41 |
| EV / EBITDA | 27.77 |
| EV / EBIT | 31.78 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.00 |
| Debt / FCF | n/a |
| Interest Coverage | 1,282.33 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 18.97% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 7.38M |
| Profits Per Employee | 1.99M |
| Employee Count | 1,571 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Concord Biotech has paid 1.03 billion in taxes.
| Income Tax | 1.03B |
| Effective Tax Rate | 24.86% |
Stock Price Statistics
The stock price has decreased by -44.21% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -44.21% |
| 50-Day Moving Average | 1,299.80 |
| 200-Day Moving Average | 1,566.16 |
| Relative Strength Index (RSI) | 42.48 |
| Average Volume (20 Days) | 19,557 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Concord Biotech had revenue of INR 11.59 billion and earned 3.13 billion in profits. Earnings per share was 29.69.
| Revenue | 11.59B |
| Gross Profit | 7.41B |
| Operating Income | 3.78B |
| Pretax Income | 4.14B |
| Net Income | 3.13B |
| EBITDA | 4.31B |
| EBIT | 3.78B |
| Earnings Per Share (EPS) | 29.69 |
Balance Sheet
The company has 3.31 billion in cash and 16.07 million in debt, with a net cash position of 3.30 billion.
| Cash & Cash Equivalents | 3.31B |
| Total Debt | 16.07M |
| Net Cash | 3.30B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 18.27B |
| Book Value Per Share | 173.32 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 63.92%, with operating and profit margins of 32.61% and 26.97%.
| Gross Margin | 63.92% |
| Operating Margin | 32.61% |
| Pretax Margin | 35.74% |
| Profit Margin | 26.97% |
| EBITDA Margin | 37.20% |
| EBIT Margin | 32.61% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 10.70, which amounts to a dividend yield of 0.90%.
| Dividend Per Share | 10.70 |
| Dividend Yield | 0.90% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 2 |
| Payout Ratio | 36.04% |
| Buyback Yield | -0.63% |
| Shareholder Yield | 0.23% |
| Earnings Yield | 2.52% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |